Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Bacterial Lysate In Children With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children of both genders aged 5 to 17 years.~2. Children with grass pollen-induced allergic rhinitis recognized and treated according to current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations.~3. Positive skin prick test to grass pollen allergens or positive specific IgE (defined as ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens.~4. Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing) in at least two recent grass pollen seasons in Poland before inclusion in the study.~5. Proper use of PMBL sublingual tablets.~6. Written informed consent obtained from parents/guardians before any study related procedures are performed.~Exclusion Criteria:~1. Patient received mechanical or any other polyvalent bacterial lysate immunostimulation within the previous 12 months before visit 1.~2. Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 years before the start of the study.~3. Vaccination performed within 3 months before the beginning of the study.~4. Deficiencies in cellular and humoral immunity.~5. Treatment with systemic corticosteroids within the last 6 months before the start of the study.~6. Pregnant or breastfeeding woman.~7. Other chronic conditions of the nose or nasal sinuses.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ismigen (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest.

Based on this trial design, predict the completion outcome and termination type (if applicable).